Across the medical device industry, R&D spending in 2011 increased despite a lethargic economy, job cuts and reorganization mandates by a number of big-name companies.
Siemens
Haemonetics closes $550M Pall blood biz buyout | Wall Street Beat
Earnings: Siemens Healthcare’s Q3 helps drive profit surge
The healthcare division of German industrial conglomerate Siemens (NYSE:SI) helped drive a nearly 70% profit surge during its fiscal 3rd quarter, with Siemens Healthcare posting a 17.0% sales increase and a whopping 4,850% bottom-line gain.
Siemens Healthcare posted profits of €396 million ($501.5 million) on sales of €3.34 billion ($4.23 billion) during the 3 months ended June 30.
FDA okays Siemens’ newest MRI system
Siemens (NYSE:SI) won FDA clearance for its latest MRI imaging system, the Magnetom Spectra 3 Tesla device.
The system aims to offer premium images with a lower financial footprint compared to other similar scanners, while providing "highly coveted" 3 Tesla technology for high-quality scans at faster speeds.
Novation details group buys for capital equipment
Novation said members of VHA Inc., UHC and Provista LLC can nab discounts of up to 71% on capital equipment fromJuly through September.
The group purchasing organization said the discounts include medical devices ranging from centrifuges and patient beds to CT scanners and nuclear medicine equipment.
Mazor’s surgical robot clears regulatory hurdles in Korea | Regulatory Roundup
Endosense CEO Keltjens goes to the races with TactiCath Quartz
Jan Keltjens is betting Endosense and its TactiCath technology can compete with 1 of the largest players in cardiac ablation: Johnson & Johnson‘s (NYSE:JNJ) BioSense Webster division.
FDA warns Siemens on diagnostic kits
The FDA late last month warned Siemens (NYSE:SI) on manufacture of its Ad Via Centaur iPTH immunoassay devices, finding that the products were adulterated.
An agency inspection of Siemens’ New York manufacturing facility found multiple quality control issues related to the products, including problems with the design review and missing documentation.
Ex-Spectranetics CEO Schulte gets probation | Legal News
Former Spectranetics (NSDQ:SPNC) CEO John Schulte was sentenced May 29 to a year of probation after being convicted in March on a single count of lying to federal investigators about his role in the allegedly illegal importation of laser medical devices for a clinical trial.
The U.S. Attorney’s Office had recommended that he be sentenced to 2 years in prison and 3 years of probation, according to the Colorado Springs Gazette.
MassDevice.com +7 | The top 7 med-tech stories for the week of April 30, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
MassDevice.com +3 | The top 3 med-tech stories for May 2, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.